Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy

Trial Information
Status: Recruiting
Location: See location...
Study Type: Observational

Hemophilia is a constitutional coagulation disorder responsible for a hemorrhagic phenotype in patients from an early age. Hemarthrosis is one of the most frequent complications in hemophiliacs and leads to the development of severe and early arthropathy, sometimes as early as childhood. To date, there is no curative treatment for these joint disorders and preventive treatments are insufficient to completely prevent joint degradation. Mesenchymal stem cells have been shown to be of therapeutic interest in the management of pathologies such as osteoarthritis and inflammatory arthritis through their anti-inflammatory, regenerative and anti-apoptotic effects. Hemophilic arthropathy is a separate condition at the border of these two diseases Our study aim to show pre-clinical interest of mesenchymal stem cell therapy in hemophilic arthropathy

Am I eligible for this trial?
Participation Requirements
Minimum Age:
Healthy Volunteers:
Accepts Healthy Volunteers

• Hemophilia A or B adult patient, with or without arthropathy

• Heathly control

Where is this trial taking place?
Other Locations
Who do I contact about this trial?
Alexandre THERON, MD
When is this trial taking place?
Start Date: October 1, 2021
Estimated Completion Date: December 31, 2022
How many participants will be in this trial?
Target number of participants: 200
Who are the authors of this trial?

This content was sourced from